Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 29 · below the Ichimoku cloud · RSI 28 (oversold) · MACD below its signal · 5% above its 52-week low
None of the 29 investors followed here reported a position in FEMY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a FEMY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for FEMY.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.1 | 6.5 | -26.3 | -13.1 | 6.0 | -46.0 | -31.6 | 19.9 | -37.0 | -18.5 | −84.7% | ||
| 2025 | 7.3 | 33.1 | -20.4 | -7.2 | -24.1 | 9.8 | -14.2 | -57.2 | -0.8 | 81.0 | 58.6 | -43.0 | −47.6% |
| 2024 | -23.3 | 135.3 | -11.9 | -18.1 | -7.1 | -3.4 | -0.9 | 3.5 | -5.1 | 19.8 | -15.8 | -1.8 | +12.8% |
| 2023 | 34.6 | -9.2 | -1.4 | -19.8 | -19.5 | -27.1 | 7.8 | -19.8 | 575.7 | -50.3 | -35.7 | 2.4 | +8.3% |
| 2022 | -23.3 | -0.7 | -23.9 | -27.4 | -6.1 | 56.5 | -29.5 | 0.0 | -33.5 | 11.5 | -14.3 | -16.7 | −76.9% |
| 2021 | -10.0 | 9.0 | -13.4 | 0.6 | -22.4 | -27.5 | −51.9% |
Buy / hold / sell counts
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.